

بسم الله الرحمن الرحيم

Sudan University of Science and Technology
College of Graduate Studies

**Comparative Study on Myocardial
Perfusion Scintigraphic Agents
(²⁰¹Tl-Thallous-Chloride, ^{99m}Tc-MIBI, and ^{99m}Tc-Tetrofosmin)**

Thesis submitted in Partial Fulfillment of M.Sc
Degree in Nuclear Medicine

Presented by: AHMED ABBAS ABDELSALAM

Supervision: Dr. ADAM KHATIR SAM

March, 2006

DEDICATION

I would like to dedicate this work to my family that continues to amaze me.

ACKNOWLEDGMENT

First, I thank my supervisor Dr. Adam Khatir Sam, for his continuous support in the M.Sc. program. Sam was always there to listen and to give advice. He taught me how to ask questions and express my ideas. He showed me different ways to approach a research problem and the need to be persistent to accomplish any goal. He was always there to meet and talk about my ideas, to proofread and mark up my papers and chapters, and to ask me good questions to help me think through my problems (whether analytical or computational).

Special thanks go to my colleagues at Radiation & Isotope Centre of Khartoum (RICK), who help me in this research either by encouragement or give me a lot of time to finish this research. I acknowledge the fact that no one can work in isolation from colleagues, residents, fellows, and student.

Last, but not least, I thank my family: my parents, for giving me life in the first place, for educating me with aspects from both arts and sciences, for unconditional support and encouragement to pursue my interests, even when the interests went beyond boundaries of language, field and geography.

LIST OF TABLES

Table.3.1: Natural radioisotopes of thallium.....	16
Table.3.2: Artificially produced thallium radioisotopes.....	17
Table.3.3: Radiation attenuation by lead shielding.....	20
Table.3.4: Thallium-201 decay chart and half-life 73.1 hours.....	20
Table.3.5: Radiation Dose Estimation for ^{201}Tl -Thallous Chloride injection.....	26
Table.4.1: Radiation attenuation by lead shielding.....	41
Table.4.2: Physical decay chart of $^{99\text{m}}\text{Tc}$ (half-life 6.02 hours)	41
Table.4.3: Percentages of $^{99\text{m}}\text{Tc}$ -MIBI (fixed activity 20 mCi).....	45
Table.4.4: Biological (T_{bio}) and effective (T_{eff}) clearance of MIBI.....	51
Table.4.5: Estimated radiation absorbed dose from $^{99\text{m}}\text{Tc}$ -Sestamibi.....	52
Table.4.6: Selected adverse events reported in > 0.5% of patients who recorded $^{99\text{m}}\text{Tc}$ -MIBI in Cardiac Clinical Studies.....	54
Table.5.1: Human Biodistribution* (% injected activity) of $^{99\text{m}}\text{Tc}$ -Tetrofosmin in selected organs.....	62
Table.5.2: Estimated absorbed radiation dose of $^{99\text{m}}\text{Tc}$ -Tetrofosmin injection.....	63
Table.6.1: Tracers for myocardial perfusion imaging.....	67

LIST OF FIGURES

Fig.2.1: Anatomy of the heart.....	6
Fig.3.1: Thallium-201 decay scheme.....	19
Fig.4.1: Structure of MIBI ((2-methoxy-isobutyl-isonitrile).....	38
Fig.4.2: Decay scheme of ^{99m}Tc	40
Fig.4.3: TLC plate diagram.....	48
Fig.5.1: Structural formula of Tetrofosmin.....	57
Fig.5.2: Clearance of injected ^{99m}Tc -tetrofosmin dose under resting and exercise.....	62
Fig.6.1: Relationship between myocardial blood flow and uptake of various perfusion tracers.....	69
Fig.6.2: Mechanism of uptake of the three agents.....	70
Fig.6.3: Comparison of the image quality obtained using the three agents...	71
Fig.6.3: Comparison of diagnostic accuracy.....	73

ABBREVIATIONS

>	Greater than
<	Lesser than
=	Equal
ATP	Adenosine Triphosphate
AV node	Atrioventricular node
B ⁻	Beta emitter
Ca ²⁺	Calcium
CI	Cardiac Index
cm	centimeter
CO ₂	Carbon dioxide.
COP	Cardiac Output
EC	Electron Capture
ECG	Electrocardiography
FDA	Food and Drug Administration.
g	gram
QC	Quality Control
GIT	Gastrointestinal Tract
H	Hydrogen
Hg	Mercury element
HL	Half Life
HPLC	High-performance liquid chromatography
IV	Intravenous
K ⁺	Potassium
keV	Kilo electron Volt
LAL	Limulus Amebocyte Lysate

LD	Lethal Dose
Lt	left
MBq	Mega Becquerel
mCi	millicurie
MeV	Mega electron Volt
mGy	Milli Gray
MIBI	Methoxy-Isobutyl Isonitrile
ml/min	milliliter per minute
MPI	Myocardial Perfusion Imaging
⁹⁹ Mo	molybdenum -99
MVO ₂	Myocardial Oxygen Consumption
N	Neutron
Na ⁺	Sodium
NM	Nuclear Medicine
NRC	Nuclear Regulatory Commission
O ₂	Oxygen
P	Proton
Pb	Lead element
pH	Potential of Hydrogen
Rt	right
SA node	Sinoatrial node
SPECT	Single Photon Emission Computed Tomography
^{99m} Tc	Technetium-99m
²⁰¹ Tl	Thallium
TLC	Thin-Layer Chromatography
USP	United States pharmacopeia.
Y	Gamma ray

TABLE OF CONTENTS

CHAPTER ONE: INTRODUCTION	1
 CHAPTER TWO: ANATOMY, PHYSIOLOGY, & PATHOLOGY	
Introduction.....	4
2.2. Anatomy.....	4
2.3. The Heart Physiology.....	7
2.3.1. Properties of the Cardiac Muscle.....	7
2.3.1.1. Contractility.....	8
2.3.1.2. Rhythmicity (automaticity)	8
2.3.1.3. Excitability (Irritability)	9
2.3.1.4. Conductivity.....	9
2.3.2. Cardiac cycle.....	10
2.3.3. Cardiac output.....	11
2.3.4. Regulation of the Stroke Volume.....	12
2.3.5. Metabolism of Cardiac Muscle.....	13
2.3.6. The passage of blood through heart.....	13
2.3.7. Myocardial Blood Supply.....	14
2.4. Pathology of the Heart.....	14
 CHAPTER THREE: ²⁰¹Tl THALLOUS-CHLORIDE	
3.1. Chemistry.....	16
3.1.1. Radioisotopes.....	16
3.1.2 Chemical reactions of the element	17
3.2. Production and Decay.....	18
3.2.1 External Radiation.....	19
3.3. Quality Control of Thallous Chloride- ²⁰¹ TlCl.....	20
3.3.1. Physiochemical Tests	21
3.3.1.1. Physical Characteristics	21

3.3.1.2. Radionuclidic Purity.....	21
3.3.1.3. Radiochemical purity.....	22
3.3.2. Biological Tests.....	22
3.3.2.1. Sterility.....	22
3.3.2.2. Apyrogenicity.....	22
3.3.2.3. Toxicity.....	23
3.4. Administration and Biodistribution.....	23
3.4.1. Mechanism of Thallous-Chloride Localization.....	23
3.4.2. Biodistribution of Thallous-chloride.....	25
3.4.3. Radiation Dosimetry.....	26
3.4.4. Redistribution of Thallium.....	27
3.5. Clinical Applications of Thallous-Chloride.....	28
3.6.1. Procedure	29

CHAPTER FOUR: ^{99m}Tc-SESTAMIBI

4.2. Introduction.....	32
4.2. Chemistry.....	32
4.3. Production and Decay.....	33
4.3.1. Synthesis of MIBI.....	34
4.3.1.1. Synthesis of N- (2-methylallyl) formamide [1].....	34
4.3.1.2. Synthesis of N-(2-methoxy-isobutyl) formamide [II].	34
4.3.1.4. Synthesis of 2-methoxy-isobutyl-isocyanide, MIBI[III]	35
4.3.1.4. Synthesis of Tetra-(2-methoxy-isobutyl-isocyano) Copper tetrafluororate [IV]	36
4.3.2. Preparation of MIBI Chelate.....	36
4.3.3. Formulation of ^{99m} Tc-MIBI Kit.....	37
4.3.4. Instructions for preparation of ^{99m} Tc-MIBI for Injection....	38
4.3.5. Physical Characteristics.....	39

4.3.5.1. External Radiation.....	40
4.4. Quality Control of ^{99m}Tc -MIBI.....	42
4.4.1. Physiochemical Tests.....	42
4.4.1.1. Physical Characteristics ^{99m}Tc -MIBI.....	42
4.4.1.2. Radionuclidic Purity.....	42
4.4.1.3. Chemical Purity.....	43
4.4.1.4. Radiochemical Purity.....	44
4.4.2. Biological Tests.....	49
4.5. Administration and Biodistribution.....	49
4.5.1. Mechanism of ^{99m}Tc -MIBI Localization.....	49
4.5.2. Diffusion and mitochondrial Binding.....	49
4.5.3. Pharmacokinetics.....	50
4.5.4 Elimination.....	51
4.5.5. Radiation Dosimetry.....	52
4.6. Application of ^{99m}Tc -MIBI.....	53
4.6.1. Procedures.....	55
CHAPTER FIVE: ^{99m}Tc-TETROFOSMIN	
5.1. Introduction.....	57
5.2. Chemistry.....	57
5.3. Preparation of ^{99m}Tc -Tetrofosmin Complex	58
5.4. Quality Control.....	58
5.5. Pharmacokinetics.....	60
5.5.1. Dosage and administration.....	60
5.5.2. Mechanism of ^{99m}Tc -Tetrofosmin Localization.....	60
5.5.3. Biodistribution.....	60
5.5.4. Cardiac ^{99m}Tc -tetrofosmin clearance.....	61
5.5.5. Radiation Dosimetry.....	62
5.6. Application of ^{99m}Tc -Tetrofosmin.....	64

CHAPTER SIX: SPECIFICITY, SENSITIVITY AND ACCURACY OF MYOCARDIAL PERFUSION AGENTS

6.1. The ideal myocardial perfusion tracer.....	68
6.2. Sensitivity/Specificity of ^{201}Tl -Thallous Chloride.....	72.
6.3. Sensitivity/Specificity of $^{99\text{m}}\text{Tc}$ -MIBI and $^{99\text{m}}\text{Tc}$ -Tetrofosmin.....	72
6.4. Advantages and disadvantages $^{99\text{m}}\text{Tc}$ agents versus ^{201}Tl	73
CONCLUSION AND RECOMMENDATION	74
REFERENCES.....	76

ABSTRACT

Myocardial perfusion imaging plays an important role in the evaluation of coronary artery diseases. As the title suggests, the central aim of this comparative study is to pinpoint the most ideal tracer for myocardial perfusion imaging from among several radiopharmaceuticals now available for routine nuclear medicine practice, namely ^{201}Tl -Thallous Chloride, $^{99\text{m}}\text{Tc}$ -Sestamibi, and $^{99\text{m}}\text{Tc}$ -Tetrofosmin. This study attempts to present comprehensive review for each radiopharmaceutical about its chemistry and preparation, quality control, pharmacokinetics (administration, Biodistribution, mechanism of localization, and clearance routines), contraindications and radiation dosimetry. This comparative review revealed that $^{99\text{m}}\text{Tc}$ -Sestamibi and $^{99\text{m}}\text{Tc}$ -Tetrofosmin have similar characteristics and superior over ^{201}Tl -thallous chloride with respect to sensitivity and specificity. The $^{99\text{m}}\text{Tc}$ -Sestamibi was found to be the most ideal radiopharmaceutical for myocardial perfusion imaging because of its long myocardial resistance time as well as adequate myocardial extraction that allow enough time to accomplish the study, providing images of higher counts density and superior quality compared with thallium-201 or tetrofosmin, optimum radiation dosimetry, availability which is very important factor that make its superior of all.

ملخص

تصوير أوعية عضلة القلب يلعب دورا هاما في تحديد درجة لصابة عضلة القلب بالأمراض . يتضح من عنوان هذه الدراسة البحثية المقارنة أن الهدف منها هو الوصول الي أفضل مادة صيدلانية موسومة بمادة أشعاعية (*Radiopharmaceutical*) من بين عدة مواد تستخدم في تصوير عضلة القلب موجودة حاليا في مجل الطب النووي وهي ($^{99m}\text{Tc-MIBI}$ و ^{99m}Tc)

Tetrofosmin و $^{201}\text{TlCl}$). في هذا البحث نحاول تقديم أستمعرض شامل عن كل المواد

الصيدلانية المستخدمة كل على حدا، متناولين الخصائص الكيميائية ، طرق تصنيعها وتحضيرها، ضبط الجودة ، كيفية إعطاؤها، توزيعها الحيوي وتخلص الجسم منها ، الجرعة الممتصة و الأعرض الجانبية.

وضحت هذه الدراسة أن كل من $^{99m}\text{Tc-MIBI}$ و $^{99m}\text{Tc-Tetrofosmin}$ اشتراكهما

في الصفات أكثر من اختلافهما، لكن لستخدامهما في نفس الوقت أفضل من أستخدم مادة ^{201}Tl

Cl وذلك وفق نتائج الحساسية والنوعية. وجدنا من خلال هذه الدراسة أن أفضل مادة صيدلانية يمكن

أستخدمها لتصوير عضلة القلب هي $^{99m}\text{Tc-MIBI}$ نسبة لسرعة أمتصاصها وطول بقائها داخل

انسجة العضلة مما يتيح زمن كافي لانجاز الفحص، ايضا يعطي صور دقيقة وذلت نوعية عالية بالمقارنة

مع تلك التي تعطيها المركبت الأخرى، زد على ذلك قلة الجرعة الممتصة، وتعد وفرته تجاريا من أهم

الأسباب التي جعلته الأفضل من غيره.